Journal of Antimicrobial Chemotherapy (2000) 46, 229-234
© 2000 The British Society for Antimicrobial Chemotherapy
A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)
a Division of Infectious Diseases, Department of Medicine, Wayne State University School of Medicine, Detroit, MI 48201; b Schering–Plough Research Institute, Kenilworth, NJ 07033, USA
We investigated the in vitro susceptibilities of clinical and laboratory-selected Aspergillus spp. to posaconazole, and compared the results with those obtained for amphotericin B, itraconazole and voriconazole. Conidial suspensions from clinical isolates (284 Aspergillus fumigatus, 66 Aspergillus niger, 31 Aspergillus flavus and 43 Aspergillus spp.) and laboratory-selected resistant A. fumigatus isolates (15 resistant to amphotericin B, 25 to itraconazole and 12 to voriconazole) were prepared and their susceptibilities to various antifungal agents determined using a previously described broth macrodilution technique. The geometric mean MICs (mg/L) of posaconazole for A. fumigatus (0.17 ± 0.11) and non-A. fumigatus aspergilli (0.16 ± 0.28) were significantly lower (P 0.05) than those for amphotericin B, itraconazole and voriconazole. Amphotericin B-resistant A. fumigatus isolates were as susceptible to posaconazole as the parental strain. Itraconazole- and voriconazole-resistant isolates showed low-level (two- to three-fold increase in MICs) cross-resistance to posaconazole. The minimum fungicidal concentrations (mg/L) of posaconazole for A. fumigatus (n = 58) and non-A. fumigatus aspergilli (n = 40) were 4.45 ± 2.70 (range 0.25–8) and 4.14 ± 3.03 (range 0.5–8), respectively. Time–kill studies showed that the fungicidal activity of posaconazole against A. fumigatus is time- and concentration-dependent (for example, posaconazole 4 mg/L killed >99% of A. fumigatus conidia within 24 h). These results suggest that overall, posaconazole has better activity and a smaller range of MICs for Aspergillus spp., including those with reduced susceptibility to amphotericin B, itraconazole and voriconazole.
* Correspondence address. Department of Medicine, Wayne State University, 427 Lande Building, 550 E. Canfield, Detroit, MI 48201, USA. Tel. +1-313-577-1931; Fax. +1-313-993-0302; E-mail: aa1388{at}wayne.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. I. Morris Posaconazole: A new oral antifungal agent with an expanded spectrum of activity Am. J. Health Syst. Pharm., February 1, 2009; 66(3): 225 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Guinea, S. Recio, T. Pelaez, M. Torres-Narbona, and E. Bouza Clinical Isolates of Aspergillus Species Remain Fully Susceptible to Voriconazole in the Post-Voriconazole Era Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3444 - 3446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. de la Escalera, A. I. Aller, E. Lopez-Oviedo, A. Romero, A. I. Martos, E. Canton, J. Peman, P. G. Martos, and E. Martin-Mazuelos Activity of BAL 4815 against filamentous fungi J. Antimicrob. Chemother., May 1, 2008; 61(5): 1083 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Canton, J. Peman, A. Espinel-Ingroff, E. Martin-Mazuelos, A. Carrillo-Munoz, and J. P. Martinez Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts J. Antimicrob. Chemother., January 1, 2008; 61(1): 135 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Soczo, G. Kardos, P. M. McNicholas, E. Balogh, L. Gergely, I. Varga, B. Kelentey, and L. Majoros Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species J. Antimicrob. Chemother., November 1, 2007; 60(5): 1004 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. McLellan, S. M. Aquino, D. R. Mason, J. M. Kinyon, and R. K. Myers Use of Posaconazole in the Management of Invasive Orbital Aspergillosis in a Cat J. Am. Anim. Hosp. Assoc., July 1, 2006; 42(4): 302 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O. Gubbins, G. Krishna, A. Sansone-Parsons, S. R. Penzak, L. Dong, M. Martinho, and E. J. Anaissie Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 1993 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sabatelli, R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris, R. Hare, D. Loebenberg, T. A. Black, and P. M. McNicholas In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2009 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Krishnan, E. K. Manavathu, and P. H. Chandrasekar A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus J. Antimicrob. Chemother., June 1, 2005; 55(6): 914 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Trama, E. Mordechai, and M. E. Adelson Detection of Aspergillus fumigatus and a Mutation That Confers Reduced Susceptibility to Itraconazole and Posaconazole by Real-Time PCR and Pyrosequencing J. Clin. Microbiol., February 1, 2005; 43(2): 906 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Courtney, A. Sansone, W. Smith, T. Marbury, P. Statkevich, M. Martinho, M. Laughlin, and S. Swan Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease J. Clin. Pharmacol., February 1, 2005; 45(2): 185 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Munayyer, P. A. Mann, A. S. Chau, T. Yarosh-Tomaine, J. R. Greene, R. S. Hare, L. Heimark, R. E. Palermo, D. Loebenberg, and P. M. McNicholas Posaconazole Is a Potent Inhibitor of Sterol 14{alpha}-Demethylation in Yeasts and Molds Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3690 - 3696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Castro, M. C. Serrano, B. Flores, A. Espinel-Ingroff, and E. Martin-Mazuelos Comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with a Modified NCCLS M38-A Method To Determine the Activity of Voriconazole against Clinical Isolates of Aspergillus spp. J. Clin. Microbiol., September 1, 2004; 42(9): 4358 - 4360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Courtney, E. Radwanski, J. Lim, and M. Laughlin Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men Antimicrob. Agents Chemother., March 1, 2004; 48(3): 804 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Lodge, E. D. Ashley, M. P. Steele, and J. R. Perfect Aspergillus fumigatus Empyema, Arthritis, and Calcaneal Osteomyelitis in a Lung Transplant Patient Successfully Treated with Posaconazole J. Clin. Microbiol., March 1, 2004; 42(3): 1376 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Xiao, V. Madison, A. S. Chau, D. Loebenberg, R. E. Palermo, and P. M. McNicholas Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14{alpha}-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole Binding Antimicrob. Agents Chemother., February 1, 2004; 48(2): 568 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Li, N. Brown, A. S. Chau, J. L. Lopez-Ribot, M. T. Ruesga, G. Quindos, C. A. Mendrick, R. S. Hare, D. Loebenberg, B. DiDomenico, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans J. Antimicrob. Chemother., January 1, 2004; 53(1): 74 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Courtney, S. Pai, M. Laughlin, J. Lim, and V. Batra Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults Antimicrob. Agents Chemother., September 1, 2003; 47(9): 2788 - 2795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Van Epps, M. Feldmesser, and E. G. Pamer Voriconazole Inhibits Fungal Growth without Impairing Antigen Presentation or T-Cell Activation Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1818 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Manavathu, G. J. Alangaden, and P. H. Chandrasekar Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus J. Antimicrob. Chemother., June 1, 2003; 51(6): 1423 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Mann, R. M. Parmegiani, S.-Q. Wei, C. A. Mendrick, X. Li, D. Loebenberg, B. DiDomenico, R. S. Hare, S. S. Walker, and P. M. McNicholas Mutations in Aspergillus fumigatus Resulting in Reduced Susceptibility to Posaconazole Appear To Be Restricted to a Single Amino Acid in the Cytochrome P450 14{alpha}-Demethylase Antimicrob. Agents Chemother., February 1, 2003; 47(2): 577 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Warris, C. M. Weemaes, and P. E. Verweij Multidrug Resistance in Aspergillus fumigatus N. Engl. J. Med., December 26, 2002; 347(26): 2173 - 2174. [Full Text] [PDF]
|
|
|
|
|
|
J. Mosquera and D. W. Denning Azole Cross-Resistance in Aspergillus fumigatus Antimicrob. Agents Chemother., February 1, 2002; 46(2): 556 - 557. [Abstract] [Full Text] [PDF]
|
|